Genxrose-CV 10 Capsule is a combination medication containing Rosuvastatin 10 mg and Clopidogrel 75 mg, indicated for the management of cardiovascular diseases. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), thereby reducing the risk of atherosclerosis and related cardiovascular events. Clopidogrel, an antiplatelet agent, inhibits platelet aggregation by selectively and irreversibly blocking the P2Y12 ADP receptor on platelet surfaces, preventing thrombus formation. The synergistic effect of these agents makes Genxrose-CV 10 suitable for patients at high risk of myocardial infarction, stroke, or peripheral arterial disease, particularly those with established coronary artery disease or recent acute coronary syndrome. It is essential to administer this medication under medical supervision, with regular monitoring of lipid profiles, liver function tests, and bleeding parameters due to the risk of hemorrhagic complications associated with Clopidogrel. Contraindications include active pathological bleeding, hypersensitivity to either component, and severe hepatic impairment. Patients should be advised on adherence to lifestyle modifications alongside pharmacotherapy to optimize cardiovascular outcomes. Genxrose-CV 10 Capsule should be stored in a cool, dry place away from direct sunlight and out of reach of children.